Ascendis Pharma Reports Third Quarter 2025 Financial Results

Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® - Q3 2025 operating profit of €11.0 million - TransCon® CNP (navepegritide) under FDA Priority Review for the ...
The Lancet

Scaling an intervention for the engagement of people with HIV who inject drugs into care in Viet Nam: an implementation-effectiveness, cluster-randomised trial

A tailored approach with rapid needs assessment before and during implementation to address local testing site barriers in ...